Cancer research

CYPIDES

This is a phase 1 safety and pharmacokinetics study with ODM-208 trial medication in patients with metastatic castration-resistant prostate cancer.

Principal investigator: Tapio Utriainen

https://clinicaltrials.gov/ct2/show/NCT03436485  

THORIUM PSMA

A phase 1 study to evaluate thorium-227 labeled antibody-chelator conjugate (BAY 2315497) in the treatment of patients with metastatic castration-resistant prostate cancer

Principal investigator: Katriina Peltola

https://clinicaltrials.gov/ct2/show/NCT03724747

BAYER20511

Open-label multicenter study to assess radium-223 bio-distribution in participants with bone metastatic castration-resistant prostate cancer

Principal Investigator: Katriina Peltola

https://clinicaltrials.gov/ct2/show/NCT04521361

KEYNOTE-991

A phase 3, randomized, double-blind trial of pembrolizumab (MK-3475), enzalutamide and androgen deprivation therapy (ADT) versus placebo, enzalutamide and ADT in participants with metastatic hormone-sensitive prostate cancer

Principal Investigator: Katriina Peltola

https://clinicaltrials.gov/ct2/show/NCT04934722

No ongoing studies at this time.

NIS793B12201

A phase II open-label randomized multicenter study of NIS793 ( +/- spartalizumab ) in combination with SOC chemotherapy gemsitabine/nab-paclitaxel, and gemsitabine/nab-paclitaxel alone in first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)

Principal investigator: Katriina Peltola

https://clinicaltrials.gov/ct2/show/NCT04390763

NIS793B12301

A phase III, randomized, double-blind study in which NIS793 or placebo has been combined with gemsitabine/nab-paclitaxel chemotherapy in first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).

Principal investigator: Katriina Peltola

https://clinicaltrials.gov/ct2/show/NCT04935359

ALL (ACUTE LYMPHOBLASTIC LEUKEMIA)

ALLTOGETHER

A treatment study protocol of children (1–17 years of age) and young adults (18–45 years of age) with acute lymphoblastic leukemia (ALL)

Person responsible for the study: Ulla Wartiovaara-Kautto

EWALL-INO

A first-line treatment study for patients of age > 55 with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

Person responsible for the study: Ulla Wartiovaara-Kautto

PONATINIB-3001

First-line treatment study comparing ponatinib and imatinib administered in combination with reduced-intensity chemotherapy, in patients with recently diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)

Person responsible for the study: Kimmo Porkka

EWALL-PH-03

An open label, three-arm, randomized phase II study to compare the safety and efficacy of ponatinib in combination with either chemotherapy or blinatumomab with imatinib plus chemotherapy as primary therapy for patients aged 55 years and older who have Philadelphia chromosome-positive (Ph+ or BCR- ABL1+) acute lymphoblastic leukemia (ALL)

Person responsible for the study: Kimmo Porkka

SCANALL

SCAN ALL – Nordic study on the occurrence of mutations in patients with Philadelphia chromosome-positive acute lymphocytic leukemia (Ph+ALL) and chronic myeloid leukemia (CML)

Person responsible for the study: Kimmo Porkka

AML (ACUTE MYELOID LEUKEMIA)

CHDM201H12101C

An open-label study of combination therapy with HDM201 drug and MBG453 or venetoclax in patients who have acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)

Person responsible for the study: Kimmo Porkka

CVOB560A12101

A phase 1b multicenter study of VOB560 study preparation in combination with MIK665 study preparation in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL), acute myeloid leukemia (AML), or multiple myeloma (MM)

Person responsible for the study: Kimmo Porkka

HO150, AMLSG 29-18

An open-label, randomized, double-blind placebo-controlled multicenter study of ivosidenib or enasidenib in combination with induction and consolidation chemotherapy followed by a maintenance therapy in patients with newly diagnosed IDH1- or IDH2-mutated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS-EB2) with excess blasts, and who are eligible for intensive chemotherapy.

Person responsible for the study: Mika Kontro

HO156, AMLSG 28-18

A phase III open-label, randomized multicenter study with gilteritinib or midostaurine in combination with induction and consolidation chemotherapy followed by a one-year maintenance treatment period in patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) or myelodysplastic syndrome with excess blasts (MDS-EB2), and who are eligible for intensive chemotherapy.

Person responsible for the study: Mika Kontro

VenEx, FLG-V001

An open-label study in which venetoclax is provided in combination with azacitidine for patients with acute myeloid leukemia selected using ex vivo drug sensitivity screening. 

Person responsible for the study: Mika Kontro

LOXO-IDH-20001

A phase 1 study for assessment of oral LY3410738 in patients with advanced hematologic malignancies with IDH1 or IDH2 mutations

Person responsible for the study: Kimmo Porkka

CML (CHRONIC MYELOID LEUKEMIA)

CABL001J12301 (about to start)

An open-label, randomized, phase III multicenter study of oral asciminib versus investigator selected tyrosine kinase inhibitor (TKI) in patients with newly diagnosed Philadelphia-chromosome positive chronic myeloid leukemia in chronic phase 

Person responsible for the study: Perttu Koskenvesa

MDS (MYELODYSPLASTIC SYNDROME)

STIMULUS, CMBG453B12301

Phase III randomized, double-blind, placebo-controlled multicenter study of azacitidine with or without MBG453 study preparation for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or chronic myelomonocytic leukemia

Person responsible for the study: Mika Kontro

F59009, ENHANCE

A randomized, double-blind, multicenter study comparing the combination of magrolimab and azacitidine with azacitidine and placebo in subjects who have not received prior treatment for high-risk myelodysplastic syndrome

Person responsible for the study: Mika Kontro

MYELOFIBROSIS

INCB 57643-103

Open-label phase I study on the safety and tolerability of INCB57643 in subjects with myelofibrosis

Person responsible for the study: Minna Lehto

INCB 50465-304

Randomized, double-blind, placebo-controlled study on the use of the combination of PI3Kδ inhibitor parsaclisib and ruxolitinib in participants with myelofibrosis who have suboptimal response to ruxolitinib

Person responsible for the study: Minna Lehto

INCB 50465-313

Phase 3 randomized, double-blind, placebo-controlled study on the use of the combination of PI3Kδ inhibitor parsaclisib and ruxolitinib in participants with myelofibrosis

Person responsible for the study: Minna Lehto

MYELOMA

CC-92480-MM-001

Open-label study to assess the safety, pharmacokinetics and preliminary efficacy of CC-92480 in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma

Person responsible for the study: Pekka Anttila

ARROW2

Open-label study comparing once or twice-weekly administered carfilzomib in combination with lenalidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma

Person responsible for the study: Pekka Anttila

COBRA

Phase 3 randomized open-label study comparing combination Crd and Vrd medications (carfilzomicb + lenalidomide + dexamethasone vs. bortezomib + lenalidomide + dexamethasone) in the treatment of newly diagnosed multiple myeloma

Person responsible for the study: Juha Lievonen

CLL (CHRONIC LYMPHOCYTIC LEUKEMIA)

CJBH492A12101

Description of the study: Open-label study on treatment with JBH492 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL)

Person responsible for the study: Vesa Lindström

CLL17

Phase 3 randomized, prospective, open-label multicenter trial of ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration venetoclax plus ibrutinib in patients with previously untreated chronic lymphocytic leukemia (CLL)

Person responsible for the study: Vesa Lindström

ASTEROID

Open-label randomized phase II study in which durvalumab is administered after stereotactic body radiotherapy as adjuvant therapy to non-small cell, grade I lung cancer

Principal investigator: Anu Anttonen

https://clinicaltrials.gov/ct2/show/NCT03446547

-

ENRICH

An open-label, randomized study of rituximab+ibrutinib compared to rituximab chemotherapy in patients over 60 years of age with mantle cell lymphoma as a first-line treatment.

Principal investigator: Annika Pasanen

https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000832-13

NP30179

Phase I open-label multicenter study assessing the safety, tolerability and pharmacokinetics of RO7082859 when administered as a single agent and in combination with obinutuzumab at escalating doses to subjects with relapsed or refractory B-cell non-Hodgkin’s lymphoma who have received a fixed single dose pre-treatment of obinutuzumab

https://clinicaltrials.gov/ct2/show/NCT03075696 Principal investigator: Sirpa Leppä

JCAR

This is a phase II clinical trial to determine the efficacy and safety of JCAR017 in adult subjects with aggressive B-cell non-Hodgkin’s lymphoma.

Principal investigator: Sirpa Leppä

https://clinicaltrials.gov/ct2/show/NCT04245839

LYMRIT

This is a phase II study of a new type of antibody-radionuclide-conjugate therapy called Betalutin in relapsed non-Hodgkin’s lymphoma.

Principal investigator: Sirpa Leppä

https://clinicaltrials.gov/ct2/show/NCT01796171

POLAR BEAR

An open-label randomized phase III study comparing R-MINI-CHOP to R-MINI-CHP therapy in combination with polazuzumab-vedotin as primary treatment for elderly patients with diffuse large cell B-cell lymphoma.

Principal investigator: Sirpa Leppä

https://clinicaltrials.gov/ct2/show/NCT04332822

CJBH492A12101

Multicenter phase I/Ib open-label study with JBH492 at escalating doses in patients with recurrent or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL)

Principal investigator: Sirpa Leppä

https://clinicaltrials.gov/ct2/show/NCT04240704

GCT3013-01

Phase 1/2 open-label dose-escalation study with GEN3013 in patients with relapsed, progressive or refractory B-cell lymphoma

Principal investigator: Sirpa Leppä

https://clinicaltrials.gov/ct2/show/NCT03625037

GCT3013-02

Phase 1b/2 open-label study to assess the safety and preliminary efficacy of epcoritamab (GEN3013; DuoBody-CD3xCD20®) in combination with other agents in subjects with B-cell non-Hodgkin’s lymphoma

Principal investigator: Sirpa Leppä

https://clinicaltrials.gov/ct2/show/NCT04663347

GCT3013-05

Randomized, open-label phase 3 study to assess the efficacy of epkoritamab compared to investigator’s choice chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma

Principal investigator: Sirpa Leppä

https://clinicaltrials.gov/ct2/show/NCT04628494

HMPL-523

Open-label phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HMPL-523 in patients with relapsed or refractory lymphoma

Principal investigator: Sirpa Leppä

https://clinicaltrials.gov/ct2/show/NCT03779113

XHUTCHISON 2018-689-00US1

Open-label phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HMPL-689 in patients with relapsed or refractory lymphoma

Principal investigator: Sirpa Leppä

https://clinicaltrials.gov/ct2/show/NCT03786926

CA209-76K

Phase III, a randomized, double-blind study comparing the efficacy, safety and tolerability of adjuvant therapy with nivolumab with placebo in early-stage melanoma patients who have undergone complete resection of tumor

Principal investigator: Micaela Hernberg

https://clinicaltrials.gov/ct2/show/NCT04099251

CA030-001

Phase 1/2 first-in-human study of BMS-986249 alone and in combination with nivolumab in advanced solid tumors

Principal investigator: Micaela Hernberg

https://clinicaltrials.gov/ct2/show/NCT03369223

CA022-001

Phase 1/2a first-in-human study of BMS-986218 monoclonal antibody alone and in combination with nivolumab in advanced solid tumors.

Principal investigator: Micaela Hernberg

https://clinicaltrials.gov/ct2/show/NCT03110107

SEACAP

The effect of seasonal prophylactic influenza vaccination and factors influencing the patients’ immune- competence during anti-PD-1 treatment of patients with melanoma

Principal investigator: Micaela Hernberg

https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003616-49

EORTC 1612-MG

Combination of targeted therapy (encorafenib and binimetinib) followed by combination of immunotherapy (ipilimumab and nivolumab) versus immediate combination of immunotherapy in patients with inoperable or metastatic melanoma with BRAF V600 mutation: an EORTC randomized phase II study (EBIN), 1612-MG

Principal investigator: Micaela Hernberg

https://clinicaltrials.gov/ct2/show/NCT03235245

MK6482-005

An open-label, randomized phase 3 study of MK-6482 versus everolimus in participants with advanced renal cell carcinoma that has progressed after prior treatment.

Principal investigator: Katriina Peltola

https://clinicaltrials.gov/ct2/show/NCT04195750

MK6482-011

Drug study comparing the MK-6482 study preparation and the combination of lenvatinib and kabotzantinib in advanced renal cell carcinoma

Principal investigator: Katriina Peltola

https://clinicaltrials.gov/ct2/show/NCT04586231

MK6482-012

An open-label randomized phase 3 study on the efficacy and safety of a combination therapy of pembrolizumab, lenvatinib and beltsutifan (MK-6482) compared to a combination therapy of MK-1308A and lenvatinib or a combination therapy of pembrolizumab and lenvatinib in advanced renal cell carcinoma

Principal investigator: Katriina Peltola

https://clinicaltrials.gov/ct2/show/NCT04736706

MO42319 KATE3

Phase III randomized, double-blind, placebo-controlled multicenter study to assess the efficacy and safety of combination therapy containing trastuzumab emtansine and atezolisumab or placebo in subjects with HER2-positive and PD-L1 positive locally advanced or metastatic breast cancer who have previously received trastuzumab (and possibly pertuzumab) and taxane-based therapy (KATE3)

Principal investigator: Meri Utriainen

https://clinicaltrials.gov/ct2/show/NCT04740918

AMEERA

A randomized, double-blind phase 3 multicenter study comparing SAR439859 and palbociclib with letrozole and palbociclib in patients with ER (+), HER2 (-) breast cancer who have not received prior systemic anti-cancer treatment for advanced disease

Principal investigator: Peeter Karihtala

https://clinicaltrials.gov/ct2/show/NCT04478266

DESTINY

An open-label, multinational, multicenter, phase 3b/4 study on trastuzumab-deruxstecan in patients with previously treated locally advanced / distantly metastasized HER2-positive breast cancer, with or without baseline brain metastasis  (DESTINY - Breast12)

Principal investigator: Johanna Mattson

https://clinicaltrials.gov/ct2/show/NCT04739761

ZEST

Study assessing the efficacy and safety of niraparib compared to placebo in breast cancer patients with tumor DNA in their blood after definitive therapy (ZEST study)

Principal investigator: Tytti Ahola

https://clinicaltrials.gov/ct2/show/NCT04915755

BOLD

A randomized phase III study comparing trastuzumab, pertuzumab and docetaxel (TPD) and three cycles of chemotherapy to the current standard regimen with current adjuvant therapy as the treatments of early HER2-positive breast cancer.

Principal investigator: Heikki Joensuu

https://clinicaltrials.gov/ct2/show/NCT02625441

CA209-7FL

Phase 3 randomized, double-blind, placebo-controlled multicenter study comparing nivolumab with placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy in the treatment of high-risk, ER-positive and HER2-negative early stage breast cancer

Principal investigator: Johanna Mattson

https://clinicaltrials.gov/ct2/show/NCT04109066

IMPASSION

Phase III, randomized, double-blind, placebo-controlled multicenter study evaluating the efficacy and safety of a combination of atezolizumab (PD-L1 antibody) and two different chemotherapies versus a combination of placebo and two different chemotherapies in subjects with early relapsed HER-2, ER, and PR-negative (triple-negative) breast cancer

Principal investigator: Meri Utriainen

https://clinicaltrials.gov/ct2/show/NCT03371017

FINPROVE

A national phase 2 drug study on individual cancer treatment in advanced cancer.

Principal investigator: Katriina Peltola

https://clinicaltrials.gov/ct2/show/NCT05159245

MATINS

Phase I/II open-label, three-phase study to determine tolerated dose and follow-up separate cohorts to assess the safety, tolerability and preliminary efficacy of CLEVER-1 antibody FP-1305 in subjects with advanced cancer (gastrointestinal cancer, melanoma or ovarian cancer)

Principal investigator: Annika Pasanen

https://clinicaltrials.gov/ct2/show/NCT03733990

TILT

Phase I dose-escalation study to determine the safety of tumor necrosis factor alpha and interleukin-2 cytokine-coding oncolytic adenovirus (TILT-123) in patients with injectable solid tumor refractory to other therapies

Principal investigator: Katriina Peltola

https://clinicaltrials.gov/ct2/show/NCT04695327

CUPISCO

Phase II randomized multicenter study assessing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have received three cycles of platinum douplet chemotherapy.

Principal investigator: Pia Suonpää

https://clinicaltrials.gov/ct2/show/NCT03498521

The Comprehensive Cancer Center has currently approximately 150 ongoing studies, of which drug trials are a significant portion. In all our research activities, we adhere to the best ethical principles. We carry out the studies in accordance with good clinical practice, considering the interests of the research patient a priority. In our research activities, we also follow the Declaration of Helsinki. 

New studies can be offered to the Comprehensive Cancer Center by sending a message to uudetsyopatutkimukset@hus.fi, or directly to the researcher.

Obtaining a hospital research permit for a pharmaceutical trial requires the approval of the Ethics Committee and FIMEA, as well as a financial agreement. The total duration of the permit processing from the research offer to its approval is approximately two months. Permits and agreements can be prepared and processed simultaneously.